MX2022001069A - Composiciones y metodos para el tratamiento de la presbicia. - Google Patents

Composiciones y metodos para el tratamiento de la presbicia.

Info

Publication number
MX2022001069A
MX2022001069A MX2022001069A MX2022001069A MX2022001069A MX 2022001069 A MX2022001069 A MX 2022001069A MX 2022001069 A MX2022001069 A MX 2022001069A MX 2022001069 A MX2022001069 A MX 2022001069A MX 2022001069 A MX2022001069 A MX 2022001069A
Authority
MX
Mexico
Prior art keywords
presbyopia
methods
treatment
ophthalmic compositions
compositions
Prior art date
Application number
MX2022001069A
Other languages
English (en)
Inventor
Michael R Robinson
Mohammed Dibas
Anuradha Gore
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2022001069A publication Critical patent/MX2022001069A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con composiciones oftálmicas tópicas que comprenden uno o más componentes activos. Los componentes activos en las composiciones oftálmicas tópicas incluyen, pero no se limitan a, carbacol, yoduro de fosfolina y sus sales farmacéuticamente aceptables. En la presente, también se describen métodos para el tratamiento de la presbicia, métodos para mejorar la visión de cerca en un sujeto con presbicia y métodos para reducir el diámetro de la pupila en un sujeto con presbicia usando las composiciones oftálmicas tópicas.
MX2022001069A 2019-07-26 2020-07-24 Composiciones y metodos para el tratamiento de la presbicia. MX2022001069A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962879296P 2019-07-26 2019-07-26
PCT/US2020/043534 WO2021021646A1 (en) 2019-07-26 2020-07-24 Compositions and methods for treatment of presbyopia

Publications (1)

Publication Number Publication Date
MX2022001069A true MX2022001069A (es) 2022-02-14

Family

ID=74229810

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001069A MX2022001069A (es) 2019-07-26 2020-07-24 Composiciones y metodos para el tratamiento de la presbicia.

Country Status (9)

Country Link
US (1) US20220273605A1 (es)
EP (1) EP4003246A4 (es)
JP (1) JP2022541854A (es)
KR (1) KR20220041151A (es)
CN (1) CN114269301A (es)
AU (1) AU2020323475A1 (es)
CA (1) CA3147107A1 (es)
MX (1) MX2022001069A (es)
WO (1) WO2021021646A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11273141B2 (en) 2020-05-18 2022-03-15 Vyluma Inc. Low-dose carbachol compositions and methods for treatment of night vision disturbance
WO2022249069A1 (en) * 2021-05-26 2022-12-01 Vyluma Inc. Low-dose carbachol ophthalmic compositions with cumulative effect
TW202333700A (zh) * 2021-12-16 2023-09-01 美商倫茨治療公司 用於治療眼病之組成物及方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136177A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
WO2010125416A1 (en) * 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia

Also Published As

Publication number Publication date
KR20220041151A (ko) 2022-03-31
EP4003246A1 (en) 2022-06-01
EP4003246A4 (en) 2023-08-16
CA3147107A1 (en) 2021-02-04
CN114269301A (zh) 2022-04-01
US20220273605A1 (en) 2022-09-01
AU2020323475A1 (en) 2022-03-03
WO2021021646A1 (en) 2021-02-04
JP2022541854A (ja) 2022-09-27

Similar Documents

Publication Publication Date Title
MX2022001069A (es) Composiciones y metodos para el tratamiento de la presbicia.
PH12020551766A1 (en) Use of pilocarpine hydrochloride for the treatment of ocular conditions
MX2023003124A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
AR121843A2 (es) Formulación oftálmica y método para mejorar la presbicia
WO2016172712A3 (en) Ophthalmic composition
RU2017144173A (ru) Конструкция линзы с центральной зоной лечения с высокой положительной оптической силой и способ предотвращения и/или замедления прогрессирования миопии
TW201613588A (en) Ophthalmic composition
EP3870170A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA, MYDRIASIS AND OTHER EYE DISEASES
EA201300272A1 (ru) Применение фотоусиливающих агентов в ассоциации с рибофлавином, а также соответствующих офтальмологических композиций для перекрестного сшивания роговицы при лечении кератоконуса или других эктазийных расстройств роговицы
EP2778749A3 (en) Presbyopia lens with pupil size correction based on level of refractive error
ZA202108950B (en) Oxymetazoline compositions and methods for treating ocular disorders
PH12021550621A1 (en) Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
AU2024202353A1 (en) Compositions and methods for treating presbyopia, hyperopia, astigmatism, decreased stereopsis, and decreased contrast sensitivity
WO2023081830A3 (en) Compositions and treatments with nirogacestat
MX2022001062A (es) Peptidos para el tratamiento de degeneracion macular no exudativa y otros trastornos del ojo.
EA201990752A1 (ru) Офтальмологический состав, содержащий цитиколин, переносимый липосомой, для лечения глаукомы
MX2020010302A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares.
IN2013DE03085A (es)
WO2017152129A3 (en) Treatment of glaucoma and/or retinal diseases and formulations useful therefore
PH12021550372A1 (en) The use of alpha-2-adrenergic receptor agonists for improving vision
MX2023005031A (es) Compuesto degradante en un medicamento.
MX2020011535A (es) Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina.
PH12020550722A1 (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
MX2021016055A (es) Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis.
MX2016006256A (es) Tratamiento de glaucoma usando laquinimod.